-
Unfair to compare us to Barca: Real Madrid's Mourinho
-
Security high as France braces for new protests
-
North Korea's Kim makes unannounced visit to Chinese border city
-
White makes winning start as Fiji edge Eddie Jones's Japan
-
Fire breaks out at Hitler's mountain retreat, suspect arrested
-
Lula, Bolsonaro strike calmer tone in final Brazil election debate
-
Marc Marquez wins Australian sprint as Martin crashes out
-
'How is it possible?': Students protest Indonesian haze
-
North Korea's Kim calls for training world's 'strongest' military
-
Israel launches major West Bank operation after soldiers killed
-
Brewers edge Rays to capture World Series opener
-
Typhoon Champi knocks out power to thousands in Taiwan
-
France to deploy 70,000 police for fresh weekend protests
-
As Israeli election nears, campaign turns ugly
-
Tatum delivers as Celtics down winless Knicks
-
Oscar hopeful 'La Bola Negra' offers lessons about communicating, directors say
-
Romantasy fans ready for sleepless night as 'Court of Thorns and Roses' returns
-
Trapped: Soaring fuel costs hurt Maine lobster industry before midterms
-
De Goede hat-trick as Canada defeat England again
-
Marc Marquez beats brother Alex to Australian MotoGP pole
-
Robot Consulting Announces Receipt of Nasdaq Delisting Determination and Request to Appeal such Determination Before a Hearings Panel
-
How to Build an Emergency Fund for Your Furry Best Friend
-
5 Ways to Prepare Financially for Parenthood
-
Rubio urges Cubans to work with CIA, but warns: be discreet
-
Ebola vaccine trial begins in DR Congo
-
Leclerc tops times for Ferrari in practice for US Grand Prix
-
Travelling man Wade equals Prem try record
-
Lula, Bolsonaro lock horns in final debate before Brazil vote
-
Rescuers search for seven people in Nairobi building collapse
-
Poulter and Hatton leave LIV Golf
-
Sacha Baron Cohen revives the 'problematic dinosaur' Ali G in new film
-
Blakely vaults out of the shadow of Biles for all-around world title
-
New race in Barcelona tops 17-event '27 IndyCar season
-
Oil tops $116 with stocks mixed on earnings, AI
-
Neymar backs Flavio Bolsonaro in Brazil election
-
Trump orders lawsuit to block Alaska Senate result if Republicans lose
-
Melania Trump says she brokered truce in war-torn Ukrainian city
-
Ebola patient in Nigeria is Swiss, had not visited DR Congo: Bern
-
Leclerc tops times for Ferrari in opening practice for US Grand Prix
-
Messi receives top Spanish award from heir to throne
-
Bayern Munich coach Kompany in hospital after collapsing
-
Macron condemns 'racist terrorist attack' after deadly shooting near Paris
-
Signs point to renewed major US military ops against Iran
-
Shiffrin sidesteps slalom in 'exploration' season
-
European, Mideast foreign ministers push peace and diplomacy at Istanbul talks
-
Bayern Munich coach Kompany in hospital after collapsing: club
-
Ex-All Black centre Williams undergoes 'miracle' heart surgery
-
Alonso sees Courtois similarities in Chelsea's Penders
-
Netanyahu launches major West Bank operation after Israeli soldiers killed
-
Melania Trump announces truce in Ukrainian city 'on brink of disaster'
D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering
NEW YORK CITY, NY / ACCESS Newswire / May 26, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, closed its securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering are approximately $2.0 million (the "Offering").
D. Boral Capital LLC acted as the Exclusive Placement Agent for the Offering.
The shares of common stock were offered by the Company pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-295085), which was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on April 24, 2026.
A prospectus supplement describing the terms of the proposed registered direct offering was filed with the SEC. Once filed, it was available on the SEC's website at http://www.sec.gov. A copy of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained from D. Boral Capital LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022, or by telephone at (212) 404-7002, or by email at [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc. (NASDAQ:JUNS) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company's lead program, JOTROL(TM) -- a proprietary, enhanced bioavailability resveratrol formulation -- is currently in a Phase IIa clinical trial for Parkinson's disease. JUNS also commercializes Nugevia (TM), a consumer longevity supplement. The acquisition of ALA-002 U.S. rights further strengthens the Company's CNS pipeline by adding a next-generation, patented psychedelic NCE at a pivotal moment in U.S. regulatory policy. For more information, please visit www.jupiterneurosciences.com.
About D. Boral Capital
D. Boral Capital LLC is a premier, relationship-driven global investment bank headquartered in New York. The firm is dedicated to delivering exceptional strategic advisory and tailored financial solutions to middle-market and emerging growth companies. With a proven track record, D. Boral Capital provides expert guidance to clients across diverse sectors worldwide, leveraging access to capital from key markets, including the United States, Asia, Europe, the Middle East, and Latin America.
A recognized leader on Wall Street, D. Boral Capital has successfully aggregated approximately $35 billion in capital since its inception in 2020, executing ~400 transactions across a broad range of investment banking products.
D. Boral Capital is a member of FINRA and SIPC.
Forward-Looking Statements
Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are often indicated by terms such as "aim," "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "likely," "look forward to," "may," "objective," "plan," "potential," "predict," "project," "should," "slate," "target," "will," "would" and similar expressions and variations thereof. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Jupiter's actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in our Annual Report on Form 10-K filed on April 1, 2026. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
For more information, please contact:
Investor Relations Contact
Jupiter Neurosciences, Inc.
Christer Rosen, Chairman & Chief Executive Officer
[email protected]
D. Boral Capital LLC
Email: [email protected]
Telephone: +1 (212) 970-5150
SOURCE: D. Boral Capital
View the original press release on ACCESS Newswire
D.Moore--AMWN